The independent source for health policy research, polling, and news.
401 - 420 of 1,309 Results
Drug copayment assistance is a form of profitable charity ā and, yes, thatās an oxymoron. Amid skyrocketing drug prices, it's understandable that patients desperately need help affording medicine, especially when their health is on the line. But these programs create a mirage that perpetuates our health care systemās reckless spending.
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Hereās a collection of their appearances.
KHN gives readers a chance to comment on a recent batch of stories.
Congress is in recess, so the slower-than-average news week gives us a chance to catch up on underreported topics, like Medicareās coverage decision for the controversial Alzheimerās disease drug Aduhelm and ominous new statistics on drug overdose deaths and sexually transmitted diseases. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, and Alice Miranda Ollstein of Politico join KHNās Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Kentucky nurse Jacqueline Brewster is accused of tampering with opioids in Tennessee and West Virginia, possibly contaminating drugs given to hospital patients.
KHN staff made the rounds on national and local media this week to discuss their stories. Hereās a collection of their appearances.
The company awarded the stateās Medi-Cal Rx contract was taken over by another company, Centene. That left the state with a contractor it didnāt pick ā one that has been accused of overbilling nine other state Medicaid programs and is now under investigation by California.
President Joe Biden welcomed former President Barack Obama back to the White House this week to announce a new policy for the Affordable Care Act that would make subsidies available to more families with unaffordable employer coverage. Meanwhile, Congress struggled to find a compromise for continued federal funding of covid-19 vaccines, testing, and treatments. Tami Luhby of CNN, Shefali Luthra of The 19th, and Jessie Hellmann of CQ Roll Call join KHNās Julie Rovner to discuss these issues and more.
In the battle against covid, pharmacies became a key place for consumers to seek vaccines and testing. Some states are expanding pharmacistsā work to include directly prescribing drugs for customers who seek some routine, point-of-care tests, such as those for flu or strep throat. But doctor groups oppose the move.
Prosecutors say opioid-seeking patients drove hours to get their prescriptions filled in Celina, Tennessee, where pharmacies ignored signs of substance misuse and paid cash ā or āmonkey bucksā ā to keep customers coming back.
The South Carolina senator led the congressional pack in pharma campaign contributions for the second half of 2021. There are clear reasons.
A ³Ō¹Ļ²»“ņģČ database tracks campaign donations from drugmakers over the past 10 years.
A corporate CEOās call for a fourth mRNA shot struck those closely watching the pandemic as self-serving. It creates public pressure for a fourth dose of vaccine before government experts have time to assess the evidence and settle on the best course forward.
Billions of dollars invested in mRNA vaccines and covid research could yield health care dividends for decades to come.
Even a personal finance expert can get stuck with a huge unexpected bill for a drug. Listen up for what you need to know about "copay accumulators."
U.S. and global drug manufacturers invested in Russiaās sizable pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion. Not everyone agrees.
Medicare has proposed limiting coverage of Aduhelm, the costly new drug to treat Alzheimerās disease, and several prominent groups representing patients and their families are pressing the program to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.
Spun off from the ailing but not-quite-dead Build Back Better legislation, a popular proposal to cap out-of-pocket insulin costs at $35 a month faces tough political realities that could kill it.
Gov. Gavin Newsom has launched several initiatives to cut rising drug prices, but the savings havenāt been as monumental as he promised. And his plan to have California make its own generic drugs hasnāt gotten off the ground.
Ā© 2026 KFF